Analyst Price Target is $5.60
▲ +112.93% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lineage Cell Therapeutics in the last 3 months. The average price target is $5.60, with a high forecast of $7.00 and a low forecast of $4.00. The average price target represents a 112.93% upside from the last price of $2.63.
Current Consensus is
The current consensus among 6 investment analysts is to buy stock in Lineage Cell Therapeutics.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product for the treatment of facial lipoatrophy. In addition, the company offers various therapeutic products for the treatment of oncology, and neurological diseases and disorders, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.